The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Flu vaccines are crucial tools in protecting public health by reducing the risk of influenza illness and its complications.

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the ...

Some scientists say this year's flu shot isn't well matched to a key strain that could spread widely in the months ahead. So, ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Health officials recommend getting a flu shot or the nasal spray at the beginning of the flu season, typically in September or October, according to the CDC. Ideally, the agency says, everyone would ...

The dominant flu strain may not be well matched to the season's vaccine. Infectious disease experts, however, say folks ...